荷兰早期声门型鳞癌全国分析:发病率、生存、复发与放疗后喉切除术(2015-2021)
该全国性研究纳入2015-2021年荷兰cT1-2N0M0声门型鳞癌患者,分析发病率、生存、复发及放疗后喉切除术。2015-2019年接受放疗的826例患者5年总生存率75%、相对生存率88%、无复发生存率86%,47例(6%)行喉切除术,仅4例(0.5%)因严重放疗毒性行喉切除术。结论认为放疗肿瘤学结果优异,放疗所致喉切除极罕见。
要点
- 早期声门型鳞癌放疗后5年总生存75%、相对生存88%、无复发生存86%。
- 826例放疗患者中47例(6%)行喉切除术,仅4例(0.5%)因严重放疗毒性。
- 该全国性数据支持放疗在早期声门型鳞癌中肿瘤学结果优异。
核心结论
- 全国性研究显示早期声门型鳞癌放疗肿瘤学结果优异,放疗所致喉切除术极罕见。
研究设计与样本
- 荷兰全国性研究纳入2015-2021年诊断的cT1-2N0M0声门型鳞癌患者,共2214例。
- 其中2015-2019年接受放疗的826例患者分析生存、复发及放疗后喉切除术。
主要发现
- 826例放疗患者5年总生存率为75%,相对生存率为88%,无复发生存率为86%。
- 826例中47例(6%)行喉切除术,仅4例(0.5%)因严重放疗毒性行喉切除术。
关键数值与推荐
- 5年总生存率75%、相对生存率88%、无复发生存率86%(放疗患者,2015-2019年诊断)。
- 喉切除术发生率6%(47/826),放疗毒性所致喉切除术发生率0.5%(4/826)。
临床怎么用
- 对于早期声门型鳞癌,放疗是可获得优异肿瘤学结果的治疗选择。
- 放疗后因严重毒性需喉切除术的风险极低,可用于医患沟通。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Growing interest in new radiotherapy strategies for early-stage glottic cancer highlights the importance of reviewing current treatment outcomes. This nationwide study presents the incidence, survival, recurrences, and laryngectomies for these patients. METHODS: Patients diagnosed with cT1-2N0M0 glottic squamous cell carcinoma (SCC) between 2015 and 2021 in the Netherlands were included. Patients diagnosed between 2015 and 2019 were analyzed for survival, recurrences, and laryngectomies after radiotherapy treatment. RESULTS: A total of 2214 patients were diagnosed with early-stage glottic SCC. A total of 826 patients were treated with radiotherapy between 2015 and 2019. The 5-year overall survival, relative survival, and recurrence-free survival after radiotherapy were 75%, 88%, and 86%, respectively. Of the 826 patients, 47 (6%) underwent laryngectomy. Only four (0.5%) patients had a laryngectomy due to severe radiation toxicity. CONCLUSION: This nationwide study demonstrates that radiotherapy for early-stage glottic SCC results in excellent oncological outcomes. Radiation-induced laryngectomies for this treatment are extremely rare.
引用
- Linden SML, van Dijk BAC, Philippens MEP, et al. Early-Stage Glottic Squamous Cell Carcinoma: A Nationwide Analysis on Incidence, Survival, Recurrences, and Laryngectomies After Radiotherapy in the Netherlands (2015-2021). Head Neck. 2026. PMID: 41881555. doi:10.1002/hed.70245
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。